196 related articles for article (PubMed ID: 21208171)
1. The use of HepaRG and human hepatocyte data in predicting CYP induction drug-drug interactions via static equation and dynamic mechanistic modelling approaches.
Grime K; Ferguson DD; Riley RJ
Curr Drug Metab; 2010 Dec; 11(10):870-85. PubMed ID: 21208171
[TBL] [Abstract][Full Text] [Related]
2. Predictive utility of in vitro rifampin induction data generated in fresh and cryopreserved human hepatocytes, Fa2N-4, and HepaRG cells.
Templeton IE; Houston JB; Galetin A
Drug Metab Dispos; 2011 Oct; 39(10):1921-9. PubMed ID: 21771933
[TBL] [Abstract][Full Text] [Related]
3. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro.
Lübberstedt M; Müller-Vieira U; Mayer M; Biemel KM; Knöspel F; Knobeloch D; Nüssler AK; Gerlach JC; Zeilinger K
J Pharmacol Toxicol Methods; 2011; 63(1):59-68. PubMed ID: 20460162
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction.
Li AP; Maurel P; Gomez-Lechon MJ; Cheng LC; Jurima-Romet M
Chem Biol Interact; 1997 Nov; 107(1-2):5-16. PubMed ID: 9402946
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Normalization Methods To Predict CYP3A4 Induction in Six Fully Characterized Cryopreserved Human Hepatocyte Preparations and HepaRG Cells.
Vermet H; Raoust N; Ngo R; Esserméant L; Klieber S; Fabre G; Boulenc X
Drug Metab Dispos; 2016 Jan; 44(1):50-60. PubMed ID: 26467767
[TBL] [Abstract][Full Text] [Related]
6. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
Iga K
J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
[TBL] [Abstract][Full Text] [Related]
7. The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes.
Kato M; Chiba K; Horikawa M; Sugiyama Y
Drug Metab Pharmacokinet; 2005 Aug; 20(4):236-43. PubMed ID: 16141603
[TBL] [Abstract][Full Text] [Related]
8. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures.
Yokoyama Y; Sasaki Y; Terasaki N; Kawataki T; Takekawa K; Iwase Y; Shimizu T; Sanoh S; Ohta S
Biol Pharm Bull; 2018 May; 41(5):722-732. PubMed ID: 29445054
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 1A2 Messenger RNA is a More Reliable Marker than Cytochrome P450 1A2 Activity, Phenacetin O-Deethylation, for Assessment of Induction Potential of Drug-Metabolizing Enzymes Using HepaRG Cells.
Ogasawara A; Kato N; Torimoto N; Aohara F; Ohashi R; Yamada Y; Taniguchi H
Drug Metab Lett; 2018; 12(1):14-23. PubMed ID: 29357810
[TBL] [Abstract][Full Text] [Related]
11. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.
Grime KH; Bird J; Ferguson D; Riley RJ
Eur J Pharm Sci; 2009 Feb; 36(2-3):175-91. PubMed ID: 19013237
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based Relative Induction Score Approach.
Zuo R; Li F; Parikh S; Cao L; Cooper KL; Hong Y; Liu J; Faris RA; Li D; Wang H
Drug Metab Dispos; 2017 Feb; 45(2):198-207. PubMed ID: 28062541
[TBL] [Abstract][Full Text] [Related]
13. HepaRG culture in tethered spheroids as an in vitro three-dimensional model for drug safety screening.
Wang Z; Luo X; Anene-Nzelu C; Yu Y; Hong X; Singh NH; Xia L; Liu S; Yu H
J Appl Toxicol; 2015 Aug; 35(8):909-17. PubMed ID: 25512232
[TBL] [Abstract][Full Text] [Related]
14. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans.
Kanebratt KP; Andersson TB
Drug Metab Dispos; 2008 Jan; 36(1):137-45. PubMed ID: 17954527
[TBL] [Abstract][Full Text] [Related]
15. New Screening Criteria Setting on Evaluation of Cytochrome P450 Induction Using HepaRG Cells with Multiplex Branched DNA Technologies in Early Drug Discovery.
Ogasawara A; Torimoto N; Tsuda N; Aohara F; Ohashi R; Yamada Y; Taniguchi H
Drug Metab Lett; 2016; 10(3):152-160. PubMed ID: 27550199
[TBL] [Abstract][Full Text] [Related]
16. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.
Fahmi OA; Hurst S; Plowchalk D; Cook J; Guo F; Youdim K; Dickins M; Phipps A; Darekar A; Hyland R; Obach RS
Drug Metab Dispos; 2009 Aug; 37(8):1658-66. PubMed ID: 19406954
[TBL] [Abstract][Full Text] [Related]
17. Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction.
Ripp SL; Mills JB; Fahmi OA; Trevena KA; Liras JL; Maurer TS; de Morais SM
Drug Metab Dispos; 2006 Oct; 34(10):1742-8. PubMed ID: 16837568
[TBL] [Abstract][Full Text] [Related]
18. An 'all-inclusive' 96-well cytochrome P450 induction method: measuring enzyme activity, mRNA levels, protein levels, and cytotoxicity from one well using cryopreserved human hepatocytes.
Halladay JS; Wong S; Khojasteh SC; Grepper S
J Pharmacol Toxicol Methods; 2012; 66(3):270-5. PubMed ID: 22809809
[TBL] [Abstract][Full Text] [Related]
19. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
[TBL] [Abstract][Full Text] [Related]
20. Application of Static Models to Predict Midazolam Clinical Interactions in the Presence of Single or Multiple Hepatitis C Virus Drugs.
Cheng Y; Ma L; Chang SY; Humphreys WG; Li W
Drug Metab Dispos; 2016 Aug; 44(8):1372-80. PubMed ID: 27226352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]